OncoMatch/Clinical Trials/NCT06689163
A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone
Is NCT06689163 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including HRS-1167 tablets and Abiraterone Acetate tablets（II） for prostate cancer.
Treatment: HRS-1167 tablets · Abiraterone Acetate tablets（II） · Prednisone Acetate tablets — The purpose of this study was to observe and evaluate the tolerability, safety, and pharmacokinetics of HRS-1167 combined with abiraterone acetate tablets (II) and prednisone in patients with metastatic prostate cancer, determine the RP2D, and evaluate the effectiveness.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: systemic antitumor therapy
Exception: anti-tumor proprietary Chinese medicine allowed if interval ≥ 2 weeks
Received systemic antitumor therapy 4 weeks before starting study treatment; ... Patients who had previously received anti-tumor proprietary Chinese medicine could be enrolled if the interval between the end of treatment and the first study was not less than 2 weeks.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06689163 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic antitumor therapy disqualifies patients from enrollment.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages